Compare RMTI & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RMTI | JSPR |
|---|---|---|
| Founded | 1994 | 2018 |
| Country | United States | United States |
| Employees | 300 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.9M | 26.3M |
| IPO Year | 2022 | 2019 |
| Metric | RMTI | JSPR |
|---|---|---|
| Price | $7.75 | $0.70 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 11 |
| Target Price | $2.00 | ★ $15.50 |
| AVG Volume (30 Days) | 26.4K | ★ 717.2K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 19.22 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $69,258,000.00 | N/A |
| Revenue This Year | $8.64 | N/A |
| Revenue Next Year | $8.44 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.55 | $0.32 |
| 52 Week High | $8.40 | $2.87 |
| Indicator | RMTI | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 65.84 | 49.12 |
| Support Level | $0.80 | $0.61 |
| Resistance Level | $7.81 | $1.01 |
| Average True Range (ATR) | 0.49 | 0.10 |
| MACD | -0.09 | -0.01 |
| Stochastic Oscillator | 66.66 | 15.81 |
Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, acid, and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate, among others. The company delivers the majority of its hemodialysis concentrates products and mixers to dialysis clinics throughout the United States and internationally, utilizing its own delivery trucks and third-party carriers.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.